Dongqing Lv
Zhejiang Taizhou Hospital Luqiao Hospital (Enze Hospital) · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University · Enze Hospital affiliated Taizhou hospital of Wenzhou Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dongqing Lv as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:49 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06373094 · A Single Dose Escalation Study of HHT201 in Healthy SubjectsShanghai Synergy Pharmaceutical Sciences Co., Ltd. · unknown · Alzheimer Disease · principal investigator
- Ph1NCT05866354 · To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid MalignanciesZai Lab (Shanghai) Co., Ltd. · completed · Solid Malignancies · principal investigator
- Ph2NCT04363255 · First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLCTaizhou Hospital · unknown · Small Cell Lung Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:49 UTC. The ranking covers the 200 most relevant of 84 PubMed records, and a shared surname and initials can bring in a namesake. All 84 on PubMed
- 306 citationsRCR 18.8
- Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.J Thorac Oncol · 2022284 citationsRCR 16.2
- 208 citationsRCR 20.3
- Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).J Clin Oncol · 2023173 citationsRCR 10.8
- Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.Lancet Respir Med · 2021106 citationsRCR 5.4
- A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.Nat Med · 2025105 citationsRCR 21.8
- Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.Lancet Respir Med · 202381 citationsRCR 5.5
- Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.JAMA Oncol · 202576 citationsRCR 14.0
- Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus.Diabetes Technol Ther · 201873 citationsRCR 3.6
- 59 citationsRCR 3.5